Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 13

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
— 13,090 — 13,090 Balance at Balance at March 31, 20258,850,386 $885 $170,519,070 $(415,719)$(179,667,937)$(9,563,701)

Three Months Ended March 31, 2024AdditionalAccumulatedotherTotalCommon stockpaid-incomprehensiveAccumulatedstockholders'SharesAmountcapitallossdeficitdeficitBalance at Balance at December 31, 20238,331,161 $833 $166,548,454 $(360,896)$(171,236,031)$(5,047,640)Stock-based compensation— — 627,700 — — 627,700 Issuance of common stock, net of issuance costs50,664 5 215,108 — — 215,113 Net loss— — — — (6,755,356)(6,755,356)Foreign currency translation adjustments— — — (39,227)— (39,227)Balance at Balance at March 31, 20248,381,825 $838 $167,391,262 $(400,123)$(177,991,387)$(10,999,410)

See accompanying notes.

3

Daré Bioscience, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited) 

Three months ended March 31,20252024Cash flows from operating activitiesNet loss$(4,378,307)$(6,755,356)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization158,110 10,778 Deferred financing cost amortization17,532 659 Right-of-use asset - operating lease123,905 117,239 Stock-based compensation377,357 627,700 Loss on disposal of property and equipment— 600,000 Non-cash royalty revenue related to sale of future royalties(23,180)— Non-cash interest expense10,044 85,432 Changes in operating assets and liabilities:Accounts receivable — (67,644)Other receivables124,748 (368,817)Prepaid expenses673,510 1,304,190 Other current assets— (152,204)Other non-current assets14,535